result modestli stronger expect capit
phase recoveri asset given ortho capit
exposur mispercept exist segment
creat long-term opportun remain overweight pt
quarter driven capit report revenu
organ sell day adj impli pre-covid estim
estim mainli driven medsurg vs mse
come pre-covid estim within medsurg instrument
normal stronger due strength surgic cut blade wast
manag smoke evacu product amongst other medic
normal benefit heighten demand larger capit mainli
beds/stretch begin late march ortho normal neuro/spin
normal rel line expect although neuro
durabl impact suppli issu exhibit normal
exhibit segment margin bp ahead estim
declin bp y/i consist announc earli april
withdrew quarterli guidanc
econom sensit ortho recent revisit econom
sensit devic origin explor economi
specif look ortho correl variou econom data
unemploy given sector typic view econom
sensit despit found conclus rel weak
account look back post-financi crisi us ortho growth
clearli weak trough sever fundament issu
present price mix shift dynam unrel macro factor
think near-term disrupt clear ortho go see acut impact
term discuss given non-emerg natur
recoveri procedur model gener assum slower
recoveri ortho rel procedur howev ortho/spin
procedur gener greater profit rel procedur
therefor hospit could incentiv priorit come back ceo
kevin lobo state see reason believ ortho procedur recoveri
longer-d rel procedur rather could even lean
earlier side view
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
capit creat equal given medsurg upsid observ expect
investor revisit debat whether perform durabl lumpi
natur discuss extens transform segment
undergon initi diversifi away larger scale capit
invest higher growth end-market procedur driven via
acquisit led year medsurg consecut out-performance vs
corpor busi capit split larg capit
mako beds/stretch endo commun mobiu procedur
medic defibril etc certain pocket portfolio
beds/stretch provid modest offset period
acut busi disrupt partli seen result recal
math bed forecast increment bed revenu
point growth term headwind see larger scale capit
endo comm procedural-driven capit impact mako
forecast signific drop outright placement expect compani
entertain usage-bas leas model near-term respons
april declin context move bear case scenario although forward-
look commentari somewhat limit manag provid clariti
april trend across busi forecast declin
ortho/spin segment april medsurg/neuro declin net
translat total corpor growth declin april gener
align bear case scenario move mani larg cap
continu view april trough stop short
confirm manag convey optim improv sinc mid-april
china australia procedur restart said shift
model broadli bear case scenario includ adjust medic neuro
estim forecast medic acceler base heighten bed
demand see model organ drive bp medsurg
convers origin view neuro insul given emerg mix
neurovascular revenu busi neurotech
impact suppli disrupt see busi declin vs
prior net model impli corpor organ growth
recov respect
phase recoveri long-term durabl remain within phase recoveri
model classifi phase recoveri asset given non-
emerg procedur exposur ortho spine exposur capit
therefor gener assum slower intermediate-term recoveri
said investor long-term invest horizon
appreci durabl profil emerg compani medsurg
transform past sever year rais price target
base ep estim two-turn premium larg cap devic
peer see warrant given durabl premium growth profil
howev modestli larg cap growth peer given leverag ep
growth limit rel
deriv base case scenario multipl two-turn premium larg cap peer
see warrant given durabl premium growth prole howev modestli
larg cap growth peer given leverag ep growth limit rel
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
deliv consecut year
organ growth improv covid-
hinder acceler growth
durabl key theme driven
mako medsurg durabl acquisition-
mako penetr still earli
knee hip provid ampl
runway mix benet share gain
materi expans near term
maintain commit
view descript risk reward theme
anticip follow mako
continu expand placement
re-acceler dilut
wright medic acquisit mitig
top-line upsid synergi drive margin
back bp annual share servic
opportun erp implement
orthoped procedur pressur
recov organ
growth remain durabl post driven
mako penetr medsurg durabl
like minim given wright medic
dilut ep growth like remain
ortho recon recoveri prolong
mako medsurg capit sale
remain mute driven wright medic
broader busi disrupt
becom inefci dilut
mako driven consecut year
market growth ww knee average point
market
share servic opportun erp
implement drive margin expans
bp margin expans drive pt ep
view explan region hierarchi
research highest favor quintil
favor mix continu mako
impact
organ growth deceler y/i closer
wright medic dis-synergi dilut
greater forecast
competit environ ortho robot
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
million except ep
million
exhibit stryker segment normal
exhibit stryker chang model
neurotechnolog spine
sale
sale
sale
sale
sale
sale
good sold
good sold
current matur long-term debt
addit paid capit
chang oper asset liabil
oper activ
purchas market secur
proce sale market sec
purchas pp
invest activ
proce issuanc debt
repay debt
proce option excercis
repurchas common stock
financ activ
effect exchang rate
net chang
equival bop
equival eop
